Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ACETthis companyAdicet Bio, Inc.	$3.15	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.67	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
CRVOCervoMed Inc.	$1.42	-2.65×	3.92×	0×	-2.34×	-51.0%	0.0%	0.0%	0.0%	-148.0%	-151.0%	-32.8%	0×	0.31×	0×	4.84×	0.0%	2	-3.92	2	C
GANXGain Therapeutics, Inc.	$1.08	-5.28×	5.72×	0×	-4.48×	-46.1%	0.0%	0.0%	0.0%	-108.6%	-95.0%	-17.4%	0.04×	1.05×	0×	6.63×	0.0%	3	-6.34	2	C
HOWLWerewolf Therapeutics, Inc.	$1.02	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
IMUXImmunic, Inc.	$7.99	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
Peer median	—	-1.19×	1.18×	0×	-0.71×	-46.1%	0.0%	0.0%	0.0%	-108.6%	-95.0%	-70.4%	0.02×	0.51×	0×	4.84×	0.0%	2	-5.39	2	—